Endoscopic Sinus Surgery in Patients with Chronic Hepatic Failure Awaiting Liver Transplant

Abstract

Background Because of the need for posttransplant immunosuppression, patients with chronic liver failure requiring transplantation must be free of infection to maintain an active status on the transplant list. These patients present significant surgical risks due to coagulopathy. Here, we present our experience with endoscopic sinus surgery for medically refractory sinusitis in this patient population. Methods We created a prospective case series of seven patients undergoing 10 surgeries. Results All patients were given preoperative blood product infusions. Operative blood loss ranged from 150 to 1500 cc with an average of 495 cc. Two cases had to be stopped before completion because of bleeding obscuring visualization. The two cases with the greatest blood loss were in patients with the most severe liver disease (highest mathematical model for end-stage liver disease scores), lowest albumin, and most extensive sinus disease. All patients were returned to active status on the liver transplant list and four patients have undergone liver transplantation. Conclusion Patients with chronic hepatic disease awaiting liver transplant can be treated successfully with endoscopic sinus surgery, but significant perioperative bleeding may not be avoidable. Preoperative use of fresh frozen plasma, platelets, and sometimes albumin are necessary, and postoperative blood products may be required with more significant sinus and liver disease. NovoSeven (recombinant factor VIIa) was used on two occasions in one patient, with maximal correction of the patient's coagulopathy. Patients should be counseled on the possible need for additional procedures to adequately clear disease.